ALFRED D. STEINBERG, M.D.; H. BENFER KALTREIDER, M.D.; PARKER J. STAPLES, M.D.; EDWARD J. GOETZL, M.D.; NORMAN TALAL, M.D.; JOHN L. DECKER, M.D., F.A.C.P.
Thirteen women with lupus nephritis were hospitalized for a 10-week double-blind therapeutic trial comparing oral cyclophosphamide with placebo. Concurrent corticosteroid therapy, up to 30 mg/day of prednisone, was permitted. Patients receiving cyclophosphamide had greater improvement than did placebo-treated patients in five indexes: anti-DNA antibodies, serum complement, urine sediment, proteinuria, and extrarenal disease. There was no difference in creatinine clearance. There was a strong positive correlation between cyclophosphamide dosage and number of indexes improved. Toxic side effects of cyclophosphamide were noted.
STEINBERG AD, KALTREIDER HB, STAPLES PJ, GOETZL EJ, TALAL N, DECKER JL. Cyclophosphamide in Lupus Nephritis: A Controlled Trial. Ann Intern Med. ;75:165–171. doi: 10.7326/0003-4819-75-2-165
Download citation file:
Published: Ann Intern Med. 1971;75(2):165-171.
Autoimmune Kidney Disease, Lupus Erythematosus, Nephrology, Rheumatology.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use